Louisa Jauze
Evry, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Enhanced lysosomal glycogen breakdown is associated with liver tumorigenesis in glycogen storage disease type III.
Journal: JHEP reports : innovation in hepatology
Published: February 26, 2025
Galectin-3: a novel biomarker of glycogen storage disease type III.
Journal: Cell death discovery
Published: October 11, 2024
Synergism of dual AAV gene therapy and rapamycin rescues GSDIII phenotype in muscle and liver.
Journal: JCI insight
Published: May 26, 2023
A functional mini-GDE transgene corrects impairment in models of glycogen storage disease type III.
Journal: The Journal of clinical investigation
Published: May 04, 2023
Deep morphological analysis of muscle biopsies from type III glycogenesis (GSDIII), debranching enzyme deficiency, revealed stereotyped vacuolar myopathy and autophagy impairment.
Journal: Acta neuropathologica communications
Published: July 24, 2019
Challenges of Gene Therapy for the Treatment of Glycogen Storage Diseases Type I and Type III.
Journal: Human gene therapy
Published: July 20, 2019
Rescue of GSDIII Phenotype with Gene Transfer Requires Liver- and Muscle-Targeted GDE Expression.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: June 28, 2017
Showing 1-8 of 8
Last Updated: 09/26/2026